Menu

Insights

Home » Insights » Insights Intercept Blood System
Cerus 28/05/2020

Inactivation efficacy of INTERCEPT for a broad spectrum of viruses and parasites

Despite the diligent implementation of strategies to minimize the risk of transfusion-transmitted infections, blood recipients, who are often vulnerable due to massive bleeding or immunosuppressive treatments are still at risk.

Cerus 22/04/2020

When you live in times when every platelet concentrate counts

With the outbreak of COVID-19 maintaining adequate inventory levels for platelet concentrates may be even more challenging than ever.

Cerus 27/02/2020

Pathogen inactivation of blood components during outbreaks of infectious diseases in the European Union

The European Centre for Disease Prevention and Control (ECDC), in co-operation with the Italian National Blood Centre, organized an expert consultation meeting (April 2019) to discuss the potential role of pathogen inactivation technologies (PI) as a blood safety intervention during outbreaks of infectious diseases for which (in most cases) laboratory screening of blood donations is not...

Cerus 31/01/2020

First annual haemovigilance activity report released after universal implementation of INTERCEPT™ in France

Pathogen inactivation of platelet concentrates (PC) with the INTERCEPT Blood System has been universally implemented in metropolitan France from November 2017 onwards. Previously INTERCEPT had been deployed since 2006 in Alsace and in the French overseas departments.

Guidelines 30/10/2019

FDA Publishes New Guidance Document on Mitigating Bacterial Contamination in Platelet Components

The FDA’s final guidance document on mitigating bacterial contamination in platelet components, released on September 30, 2019, formally recognises the risk of transfusion-transmitted bacterial infections and the need for additional safety measures to protect patients.